IP Library Granted Patent US 9,782,403
Granted Patent B2
US 9,782,403 · App. 15/270,167 · Granted Oct 10, 2017

Treating sexual desire disorders with flibanserin

Inventors: Franco Borsini (Bad Waldsee, DE); Kenneth Robert Evans (Toronto, CA)
Assignee: Sprout Pharmaceuticals, Inc.
A61K31/496
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,782,403
App. No.
15/270,167
Granted
Oct 10, 2017
Kind
B2
Abstract

The invention relates to the use of fibanserin, or a pharmaceutically acceptable acid addition salt thereof, for the treatment of disorders of sexual desire.

Claims (20)

1. A method of treating a sexual disorder in a patient, wherein the sexual disorder is selected from the group consisting of loss of sexual desire, lack of sexual desire, loss of libido, libido disturbance, and frigidity, comprising administering to said patient in need thereof a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat said sexual disorder.

2. The method according to claim 1 , wherein the patient is female.

3. The method according to claim 1 , wherein the patient is male.

4. The method according to claim 1 , wherein the amount administered is between 0.1 mg to 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

5. The method according to claim 1 , wherein the amount administered is between 2 mg to 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

6. The method according to claim 1 , wherein the amount administered is in a dosage unit containing from 0.01 mg to 100 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

7. A method of treating lack of sexual desire comprising administering to said patient in need thereof a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat said lack of sexual desire.

8. The method according to claim 7 , wherein the patient is female.

9. The method according to claim 7 , wherein the patient is male.

10. The method according to claim 7 , wherein the amount administered is between 0.1 mg to 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

11. The method according to claim 7 , wherein the amount administered is between 1.0 mg to 300 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

12. The method according to claim 7 , wherein the amount administered is between 2 mg to 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

13. The method according to claim 7 , wherein the amount administered is in a dosage unit containing from 0.01 mg to 100 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

14. A method of treating loss of sexual desire in a patient comprising administering to said patient in need thereof a therapeutically effective amount of flibanserin or a pharmaceutically acceptable acid addition salt thereof to treat said loss of sexual desire.

15. The method according to claim 14 , wherein the patient is female.

16. The method according to claim 14 , wherein the patient is male.

17. The method according to claim 14 , wherein the amount administered is between 0.1 mg to 400 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

18. The method according to claim 14 , wherein the amount administered is between 1.0 mg and 300 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

19. The method according to claim 14 , wherein the amount administered is between 2 mg and 200 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

20. The method according to claim 14 , wherein the amount administered is in a dosage unit containing from 0.01 mg to 100 mg per day of flibanserin or a pharmaceutically acceptable acid addition salt thereof.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: BARCLAYS BANK PLC
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061401/0684 →
RELEASE OF SECURITY INTEREST IN SPECIFIED PATENTS Recorded Sep 9, 2022
From: THE BANK OF NEW YORK MELLON
To: SPROUT PHARMACEUTICALS, INC.
Reel/Frame 061402/0236 →
SECURITY INTEREST Recorded Feb 25, 2021
From: SPROUT PHARMACEUTICALS, INC.
To: GOODRICH, BRAXTON; WHITEHEAD, ROBERT
Reel/Frame 055407/0810 →
SECURITY INTEREST Recorded Jul 19, 2017
From: SPROUT PHARMACEUTICALS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043041/0950 →
SECURITY AGREEMENT Recorded May 25, 2017
From: ALDEN OPTICAL LABORATORIES, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; DENDREON PHARMACEUTICALS, INC.; DOW PHARMACEUTICAL SCIENCES, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; SPROUT PHARMACEUTICALS, INC.; SYNERGETICS USA, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 042584/0861 →
Priority Claims (1)
EP 01125020 · Oct 20, 2001 · regional
Continuity (8)
Continuation 14640055 · Mar 6, 2015
Continuation 14269373 · May 5, 2014
Continuation 13920354 · Jun 18, 2013
Continuation 13551036 · Jul 17, 2012
Continuation 11524268 · Sep 21, 2006
Continuation 10272603 · Oct 16, 2002
Provisional Application 60348911 · Oct 23, 2001
Related Publication 20170100392A1 · Apr 13, 2017